Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
OCS
OCS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
OCS News
Oculis Secures FDA Special Protocol Assessment for Privosegtor
4d ago
Newsfilter
Oculis Advances Non-Invasive DME Treatment Options
6d ago
Newsfilter
Oculis Highlights DME Management Study Findings
May 01 2026
Newsfilter
Oculis Completes Final Patient Visit in Phase 3 DIAMOND Program for OCS-01
Apr 20 2026
NASDAQ.COM
Completion of OCS-01 Trials Marks Key Milestone Ahead of 2026 Results
Apr 20 2026
Newsfilter
Oculis Announces 2026 Investor Conference Participation and Key Updates
Apr 07 2026
Newsfilter
Oculis Secures PRIME Designation for Privosegtor, Advancing Development
Mar 31 2026
Yahoo Finance
Oculis Receives EMA PRIME Designation for Privosegtor
Mar 31 2026
Newsfilter
Oculis Announces Upcoming Investor Conference Schedule
Mar 05 2026
Newsfilter
Oculis Reports 2025 Financial Results and Clinical Milestones
Mar 04 2026
NASDAQ.COM
Oculis Holding Reports Q4 Earnings Beat Expectations
Mar 03 2026
seekingalpha
Oculis Appoints New Chief Legal Officer to Enhance Leadership
Feb 17 2026
Newsfilter
Oculis Receives FDA Breakthrough Therapy Designation, Potential Market Exceeds $7 Billion
Jan 08 2026
Globenewswire
Oculis Receives FDA Breakthrough Therapy Designation, Potential Market Exceeds $7 Billion
Jan 08 2026
Globenewswire
Oculis Receives Breakthrough Therapy Designation, Potential Market Exceeds $7 Billion
Jan 08 2026
Yahoo Finance
US Stock Indices Hit Record Highs as Chip Stocks Rally
Jan 07 2026
NASDAQ.COM
Show More News
